Search

Your search keyword '"Pierie, J."' showing total 179 results
Start Over Author "Pierie, J."
179 results on '"Pierie, J."'

3. Omentum preservation versus complete omentectomy in gastrectomy for gastric cancer (OMEGA trial): study protocol for a randomized controlled trial

Author

Keywani, K., Eshuis, W. J., Borgstein, A. B. J., van Det, M. J., van Duijvendijk, P., van Etten, B., Grimminger, P. P., Heisterkamp, J., Lagarde, S. M., Luyer, M. D. P., Markar, S. R., Meijer, S. L., Pierie, J. P. E. N., Roviello, F., Ruurda, J. P., van Sandick, J. W., Sosef, M., Witteman, B. P. L., de Steur, W. O., Lissenberg-Witte, B. I., van Berge Henegouwen, M. I., and Gisbertz, S. S.

Published
2024
Full Text
View/download PDF

4. Omentum preservation versus complete omentectomy in gastrectomy for gastric cancer (OMEGA trial): study protocol for a randomized controlled trial

Author

MS CGO, Cancer, Keywani, K, Eshuis, W J, Borgstein, A B J, van Det, M J, van Duijvendijk, P, van Etten, B, Grimminger, P P, Heisterkamp, J, Lagarde, S M, Luyer, M D P, Markar, S R, Meijer, S L, Pierie, J P E N, Roviello, F, Ruurda, J P, van Sandick, J W, Sosef, M, Witteman, B P L, de Steur, W O, Lissenberg-Witte, B I, van Berge Henegouwen, M I, Gisbertz, S S, MS CGO, Cancer, Keywani, K, Eshuis, W J, Borgstein, A B J, van Det, M J, van Duijvendijk, P, van Etten, B, Grimminger, P P, Heisterkamp, J, Lagarde, S M, Luyer, M D P, Markar, S R, Meijer, S L, Pierie, J P E N, Roviello, F, Ruurda, J P, van Sandick, J W, Sosef, M, Witteman, B P L, de Steur, W O, Lissenberg-Witte, B I, van Berge Henegouwen, M I, and Gisbertz, S S

Published
2024

5. Omentum preservation versus complete omentectomy in gastrectomy for gastric cancer (OMEGA trial):study protocol for a randomized controlled trial

Author

Keywani, K., Eshuis, W. J., Borgstein, A. B.J., van Det, M. J., van Duijvendijk, P., van Etten, B., Grimminger, P. P., Heisterkamp, J., Lagarde, S. M., Luyer, M. D.P., Markar, S. R., Meijer, S. L., Pierie, J. P.E.N., Roviello, F., Ruurda, J. P., van Sandick, J. W., Sosef, M., Witteman, B. P.L., de Steur, W. O., Lissenberg-Witte, B. I., van Berge Henegouwen, M. I., Gisbertz, S. S., Keywani, K., Eshuis, W. J., Borgstein, A. B.J., van Det, M. J., van Duijvendijk, P., van Etten, B., Grimminger, P. P., Heisterkamp, J., Lagarde, S. M., Luyer, M. D.P., Markar, S. R., Meijer, S. L., Pierie, J. P.E.N., Roviello, F., Ruurda, J. P., van Sandick, J. W., Sosef, M., Witteman, B. P.L., de Steur, W. O., Lissenberg-Witte, B. I., van Berge Henegouwen, M. I., and Gisbertz, S. S.

Abstract

Background: Potentially curative therapy for locally advanced gastric cancer consists of gastrectomy, usually in combination with perioperative chemotherapy. An oncological resection includes a radical (R0) gastrectomy and modified D2 lymphadenectomy; generally, a total omentectomy is also performed, to ensure the removal of possible microscopic disease. However, the omentum functions as a regulator of regional immune responses to prevent infections and prevents adhesions which could lead to bowel obstructions. Evidence supporting a survival benefit of routine complete omentectomy during gastrectomy is lacking. Methods: OMEGA is a randomized controlled, open, parallel, non-inferiority, multicenter trial. Eligible patients are operable (ASA < 4) and have resectable (≦ cT4aN3bM0) primary gastric cancer. Patients will be 1:1 randomized between (sub)total gastrectomy with omentum preservation distal of the gastroepiploic vessels versus complete omentectomy. For a power of 80%, the target sample size is 654 patients. The primary objective is to investigate whether omentum preservation in gastrectomy for cancer is non-inferior to complete omentectomy in terms of 3-year overall survival. Secondary endpoints include intra- and postoperative outcomes, such as blood loss, operative time, hospital stay, readmission rate, quality of life, disease-free survival, and cost-effectiveness. Discussion: The OMEGA trial investigates if omentum preservation during gastrectomy for gastric cancer is non-inferior to complete omentectomy in terms of 3-year overall survival, with non-inferiority being determined based on results from both the intention-to-treat and the per-protocol analyses. The OMEGA trial will elucidate whether routine complete omentectomy could be omitted, potentially reducing overtreatment. Trial registration: ClinicalTrials.gov NCT05180864. Registered on 6th January 2022.

Published
2024

6. Implementation of Pelvic Floor Rehabilitation after rectal cancer surgery: A qualitative study guided by the Consolidated Framework for Implementation Research (CFIR).

Author

Bosch, N. M., Kalkdijk-Dijkstra, A. J., Broens, P. M. A., van Westreenen, H. L., Pierie, J. P. E. N., Klarenbeek, B. R., and van der Heijden, J. A. G.

Subjects
RECTAL cancer, PELVIC floor, RECTAL surgery, ONCOLOGIC surgery, PATIENT selection
Abstract

Background: Pelvic Floor Rehabilitation (PFR) is effective in a selection of patients with low anterior resection syndrome (LARS) after rectal cancer surgery. This study aimed to identify barriers and enablers to prepare for successful implementation into clinical practice. Methods: A qualitative study was performed, guided by the Consolidated Framework for Implementation Research (CFIR). Individual interviews (n = 27) and two focus groups were conducted to synthesize the perspectives of rectal cancer patients, pelvic floor (PF) physiotherapists, and medical experts. Results: Barriers were found to be the absence of guidelines about LARS treatment, underdeveloped network care, suboptimal patient information, and expectation management upfront to PFR. Financial status is frequently a barrier because insurance companies do not always reimburse PFR. Enablers were the current level of evidence for PFR, the positive relationship between patients and PF physiotherapists, and the level of self-motivation by patients. Conclusion: The factors identified in our study play a crucial role in ensuring a successful implementation of PFR after rectal cancer surgery. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Pelvic Floor Rehabilitation After Rectal Cancer Surgery: A Multicenter Randomized Clinical Trial (FORCE Trial)

Author

van der Heijden, J. A. G., Kalkdijk-Dijkstra, A. J., Pierie, J. P. E. N., van Westreenen, H. L., Broens, P. M. A., Klarenbeek, B. R., de Wilt, JHW, Stommel, MWJ, Bremers, AJA, Rosman, C, de Reuver, PR, Bouwense, SAW, van der Kolk, BM, Garms, LM, Meerten-van den Belt, K, Olde Hartman-Hofste, MRM, Peters, JWM, Olsder, L, Huizing, I, Trzpis, M, Furnee, EJB, Havenga, K, Hemmer, PHJ, van Etten, B, Koop, A, van der Heide, L, Kamphuis, D, Koopal, SA, Hoff, C, Eker, H, Junte, HHM, Schoenaker, IJH, Quaedackers, S, Bos, MJ, Gardien, H, van Sprundel, TC, de Vries, PD, Ashruf, JF, Geurts, L, Nielen, I, Pfeil, J, van Ark, M, Polle, SW, Hansson, B, Polat, F, de Vries, H, ten Berge-Groen, E, Talsma, AK, Bosker, R, Veurink, E, Papa, M, Maaskant-Braat, AJG, van den Broek, FJC, Leclercq, WKG, Slooter, GD, Caers, F, Boeijen, M, van den Broek, R, van Schaik, K, Wasowicz-Kemps, DK, Langenhoff, BS, van den Bogaard, MJ, van der Sluis, J, Arisz, D, Bruinsma, S, Hess, DA, Mulder, EJ, Wiering, B, Kok, S, Woltering, J, Raap-van Sleuwen, B, Schoonderwoerd, L, Hendriks, D, van den Elzen, N, van de Laak, I, Valk, M, van der Meij, W, van Wely, BJ, van Hoogstraten, MJ, van der Sluis, M, Paulusma, I, Mollers, MJW, Looijen, R, van der Mijle, HCJ, Pereboom, ITA, Tijink-Callenbach, PMC, Schasfoort, RA, van der Hagen, SJ, van de Meer, W, Lubberink, M, van Haskera, M, Wit, F, Jeeninga, M, ten Hoeve, R, Slootmans, FCW, Inberg, B, de Nes, L, Toonen, D, Wilmsen, MA, Buyne, O, Ferenschild, F, de Vries, M., Adamse, C, Hettema-Beets, BL, Goudswaard, MK, van der Velde, M, Elving, DW, Arends-Smit, RE, Buiter, JR, van der itte-van Aerle, I, Jansma, K, Kooistra, L, Lohof-Venema, S, Kruijer, MR, Dijkstra, G, van der erf-Elling, MA, Kats-de Boer, V, Rinsema, AM, Haarlemmer-Lutjeboer, M, van der Vegt, A, Berends-Pors, SMH, Ponstein, AJ, Klaassen, G, Nieuwint, AM, Veninga-Jansen, M, Dries-Jansen, V, Arends, FJ, Stellingwerf-Goinga, NE, Overmars, NG, van Asma, H, Beverdam, K, Ploumen, MJAC, Tijhuis, M, Visser Duiven, AH, Former, M, Smans-Kaal, MAL, Vorsterman van Oijen-Linthorst, CMJ, Hovels-Kamp, NN, Vorsteveld, LR, Vermeulen, N, Alkemade-van Veghel, A, Steentjes, LJ, Cornelisse-Theunissen, HGM, Strijbosch, J, Sniekers, S, Oerlemans-van Oijen, JMA, Hoefnagels, HMJ, Sniekers, CJDA, Biemans, S, Bomert-Wendt, Y, van Gaal, HGM, Smulders, AHCW, Adams, W, Kappen, JM, Vermeltfoort-Jansen, AM, Zegger, MGC, Vrielink, C, Slotman, HM, Claessens, NJH, Manders-de Groot, AWM, van Beuzekom-van der Vorst, CTPG, Swinkels-Nijssen, MWC, van Oeveren, P, van Leeuwen-Nellestijn, JPF, Bleijenberg, M, Valenteyn-Hidden, JJF, van Rutten-de Groot, MG, van den van der Heijden, M, Nieuwenhuizen, Boorsma, PG, Broodman, N, Elling, ME, Bokkers-Engelen, E, Hilhorst-Droppers, GH, Mein, HJC, and Gielen, M

Published
2022
Full Text
View/download PDF

9. Evaluation of PET and laparoscopy in STagIng advanced gastric cancer: a multicenter prospective study (PLASTIC-study)

Author

Brenkman, H. J. F., Gertsen, E. C., Vegt, E., van Hillegersberg, R., van Berge Henegouwen, M. I., Gisbertz, S. S., Luyer, M. D. P., Nieuwenhuijzen, G. A. P., van Lanschot, J. J. B., Lagarde, S. M., de Steur, W. O., Hartgrink, H. H., Stoot, J. H. M. B., Hulsewe, K. W. E., Spillenaar Bilgen, E. J., van Det, M. J., Kouwenhoven, E. A., van der Peet, D. L., Daams, F., van Sandick, J. W., van Grieken, N. C. T., Heisterkamp, J., van Etten, B., Haveman, J. W., Pierie, J. P., Jonker, F., Thijssen, A. Y., Belt, E. J. T., van Duijvendijk, P., Wassenaar, E., van Laarhoven, H. W. M., Wessels, F. J., Haj Mohammad, N., van Stel, H. F., Frederix, G. W. J., Siersema, P. D., Ruurda, J. P., and on behalf of the PLASTIC Study Group

Published
2018
Full Text
View/download PDF

16. Postoperative intensive care unit stay after minimally invasive esophagectomy shows large hospital variation. Results from the Dutch Upper Gastrointestinal Cancer Audit

Author

Voeten, D.M. (Daan M.), Werf, L.R. (Leonie) van der, Gisbertz, S.S. (Suzanne S.), Ruurda, J.P. (Jelle), van Berge Henegouwen, M.I., Hillegersberg, R. (Richard) van, van Det, M.J. (Marc J.), Duijvendijk, P. (Peter) van, van Esser, S. (Stijn), Etten, B. (Boudewijn) van, Harst, E. (Erwin) van der, Hartgrink, H.H. (H.), Heisterkamp, J. (Joos), Nieuwenhuijzen, G.A.P. (Gerard), Peet, D.L. (Donald) van der, Pierie, J.-P.E.N. (Jean-Pierre E.N.), Rosman, C. (Camiel), Sandick, J.W. (J.) van, Sosef, M.N. (Meindert), Wijnhoven, B.P.L. (Bas), Voeten, D.M. (Daan M.), Werf, L.R. (Leonie) van der, Gisbertz, S.S. (Suzanne S.), Ruurda, J.P. (Jelle), van Berge Henegouwen, M.I., Hillegersberg, R. (Richard) van, van Det, M.J. (Marc J.), Duijvendijk, P. (Peter) van, van Esser, S. (Stijn), Etten, B. (Boudewijn) van, Harst, E. (Erwin) van der, Hartgrink, H.H. (H.), Heisterkamp, J. (Joos), Nieuwenhuijzen, G.A.P. (Gerard), Peet, D.L. (Donald) van der, Pierie, J.-P.E.N. (Jean-Pierre E.N.), Rosman, C. (Camiel), Sandick, J.W. (J.) van, Sosef, M.N. (Meindert), and Wijnhoven, B.P.L. (Bas)

Abstract

Introduction: The value of routine intensive care unit (ICU) admission after minimally invasive esophagectomy (MIE) has been questioned. This study aimed to investigate Dutch hospital variation regarding length of direct postoperative ICU stay, and the impact of this hospital variation on short-term surgical outcomes. Materials and methods: Patients registered in the Dutch Upper Gastrointestinal Cancer Audit (DUCA) undergoing curative MIE were included. Length of direct postoperative ICU stay was dichotomized around the national median into short ICU stay ( ≤ 1 day) and long ICU stay ( > 1 day). A case-mix corrected funnel plot based on multivariable logistic regression analyses investigated hospital variation. The impact of this hospital variation on short-term surgical outcomes was investigated using multilevel multivariable logistic regression analyses. Results: Between 2017 and 2019, 2110 patients from 16 hospitals were included. Median length of postoperative ICU stay was 1 day [hospital variation: 0–4]. The percentage of short ICU stay ranged from 0 to 91% among hospitals. Corrected for case-mix, 7 hospitals had statistically significantly higher short ICU stay rates and 6 hospitals had lower rates. ICU readmission, in-hospital/30-day mortality, failure to rescue, postoperative pneumonia, cardiac complications and anastomotic leakage were not associated with hospital variation in length of ICU stay. Total length of hospital stay was significantly shorter in hospitals with relatively short ICU stay. Conclusion: This study showed significant hospital variation in postoperative length of ICU stay after MIE. Short ICU stay was associated with shorter overall hospital admission and did not negatively impact short-term surgical outcomes. More selected use of ICU resources could result in a national significant cost reduction.

Published
2021
Full Text
View/download PDF

17. LBA75 Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): A phase-III stepped-wedge cluster randomised trial

Author

van der Wilk, B.J., Eyck, B.M., Wijnhoven, B.P.L., Lagarde, S.M., Rosman, C., Noordman, B.J., Valkema, M.J., Coene, P-P., Dekker, J-W., Hartgrink, H., Heisterkamp, J., Kouwenhoven, E., Nieuwenhuijzen, G., Pierie, J-P., van Sandick, J., Sosef, M., Spaander, M., van der Zaag, E., Steyerberg, E., and van Lanschot, J.

Published
2023
Full Text
View/download PDF

25. Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer

Author

Seesing, M F J, van der Veen, A, Brenkman, H J F, Stockmann, H B A C, Nieuwenhuijzen, G A P, Rosman, C, van den Wildenberg, F J H, van Berge Henegouwen, Mark I, van Duijvendijk, P, Wijnhoven, B P L, Stoot, J H M B, Lacle, M, Ruurda, J P, van Hillegersberg, R, Baas, P C, Boerma, D, de Steur, W O, de Waard, J W D, Heisterkamp, J, van Hillo, M, Kouwenhoven, E A, Liem, M S L, van der Peet, D L, Pierie, J P E N, Plukker, J T M, Roumen, R M H, Tetteroo, G W M, van Workum, F, CCA - Cancer Treatment and Quality of Life, AGEM - Re-generation and cancer of the digestive system, Surgery, Lifelong Learning, Education & Assessment Research Network (LEARN), Damage and Repair in Cancer Development and Cancer Treatment (DARE), and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
Male, Lung Neoplasms, Esophageal Neoplasms, SURGERY, medicine.medical_treatment, Kaplan-Meier Estimate, RADICAL ESOPHAGECTOMY, Gastroenterology, Metastasis, COLORECTAL-CANCER, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], hepatic surgery, 0302 clinical medicine, Pulmonary metastasis, Medicine, Registries, Prospective cohort study, Neoadjuvant therapy, Netherlands, Liver Neoplasms, SURGICAL RESECTION, esophageal and gastric cancer, General Medicine, CHEMOTHERAPY, Middle Aged, Combined Modality Therapy, Survival Rate, Treatment Outcome, Esophagectomy, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Original Article, Female, Metastasectomy, pulmonary surgery, Erratum, medicine.medical_specialty, CARCINOMA, RECURRENCE PATTERN, Resection, LIVER METASTASES, CHEMORADIOTHERAPY, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Gastrectomy, Stomach Neoplasms, Internal medicine, Carcinoma, metastasis, Humans, Aged, esophageal and gastric surgery, business.industry, Neuroendocrine neoplasm, Cancer, LONG-TERM SURVIVAL, medicine.disease, Surgery, business, Author name, Chemoradiotherapy
Abstract

SUMMARY The standard of care for gastroesophageal cancer patients with hepatic or pulmonary metastases is best supportive care or palliative chemotherapy. Occasionally, patients can be selected for curative treatment instead. This study aimed to evaluate patients who underwent a resection of hepatic or pulmonary metastasis with curative intent. The Dutch national registry for histo- and cytopathology was used to identify these patients. Data were retrieved from the individual patient files. Kaplan–Meier survival analysis was performed. Between 1991 and 2016, 32,057 patients received a gastrectomy or esophagectomy for gastroesophageal cancer in the Netherlands. Of these patients, 34 selected patients received a resection of hepatic metastasis (n = 19) or pulmonary metastasis (n = 15) in 21 different hospitals. Only 4 patients received neoadjuvant therapy before metastasectomy. The majority of patients had solitary, metachronous metastases. After metastasectomy, grade 3 (Clavien–Dindo) complications occurred in 7 patients and mortality in 1 patient. After resection of hepatic metastases, the median potential follow-up time was 54 months. Median overall survival (OS) was 28 months and the 1-, 3-, and 5- year OS was 84%, 41%, and 31%, respectively. After pulmonary metastases resection, the median potential follow-up time was 80 months. The median OS was not reached and the 1-, 3-, and 5- year OS was 67%, 53%, and 53%, respectively. In selected patients with gastroesophageal cancer with hepatic or pulmonary metastases, metastasectomy was performed with limited morbidity and mortality and offered a 5-year OS of 31–53%. Further prospective studies are required.

Published
2020

32. Transrectus sheath pre-peritoneal (TREPP) procedure versus totally extraperitoneal (TEP) procedure and Lichtenstein technique: a propensity-score-matched analysis in Dutch high-volume regional hospitals

Author

Zwols, T. L. R., primary, Slagter, N., additional, Veeger, N. J. G. M., additional, Möllers, M. J. W., additional, Hess, D. A., additional, Jutte, E., additional, Brandsma, H. T., additional, Veldman, P. H. J. M., additional, Koning, G. G., additional, Eker, H. H., additional, and Pierie, J. P. E. N., additional

Published
2020
Full Text
View/download PDF

37. Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer : a nationwide study

Author

Seesing, M F J, van der Veen, A, Brenkman, H J F, Stockmann, H B A C, Nieuwenhuijzen, G A P, Rosman, C, van den Wildenberg, F J H, van Berge Henegouwen, Mark I, van Duijvendijk, P, Wijnhoven, B P L, Stoot, J H M B, Lacle, M, Ruurda, J P, van Hillegersberg, R, Baas, P C, Boerma, D, de Steur, W O, de Waard, J W D, Heisterkamp, J, van Hillo, M, Kouwenhoven, E A, Liem, M S L, van der Peet, D L, Pierie, J P E N, Plukker, J T M, Roumen, R M H, Tetteroo, G W M, van Workum, F, Seesing, M F J, van der Veen, A, Brenkman, H J F, Stockmann, H B A C, Nieuwenhuijzen, G A P, Rosman, C, van den Wildenberg, F J H, van Berge Henegouwen, Mark I, van Duijvendijk, P, Wijnhoven, B P L, Stoot, J H M B, Lacle, M, Ruurda, J P, van Hillegersberg, R, Baas, P C, Boerma, D, de Steur, W O, de Waard, J W D, Heisterkamp, J, van Hillo, M, Kouwenhoven, E A, Liem, M S L, van der Peet, D L, Pierie, J P E N, Plukker, J T M, Roumen, R M H, Tetteroo, G W M, and van Workum, F

Published
2019

38. Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study

Author

MS CGO, Cancer, Heelkunde Opleiding, Pathologie Pathologen staf, Divisie Beeld & Oncologie, Seesing, M F J, van der Veen, A, Brenkman, H J F, Stockmann, H B A C, Nieuwenhuijzen, G A P, Rosman, C, van den Wildenberg, F J H, van Berge Henegouwen, Mark I, van Duijvendijk, P, Wijnhoven, B P L, Stoot, J H M B, Lacle, M, Ruurda, J P, van Hillegersberg, R, Baas, P C, Boerma, D, de Steur, W O, de Waard, J W D, Heisterkamp, J, van Hillo, M, Kouwenhoven, E A, Liem, M S L, van der Peet, D L, Pierie, J P E N, Plukker, J T M, Roumen, R M H, Tetteroo, G W M, van Workum, F, MS CGO, Cancer, Heelkunde Opleiding, Pathologie Pathologen staf, Divisie Beeld & Oncologie, Seesing, M F J, van der Veen, A, Brenkman, H J F, Stockmann, H B A C, Nieuwenhuijzen, G A P, Rosman, C, van den Wildenberg, F J H, van Berge Henegouwen, Mark I, van Duijvendijk, P, Wijnhoven, B P L, Stoot, J H M B, Lacle, M, Ruurda, J P, van Hillegersberg, R, Baas, P C, Boerma, D, de Steur, W O, de Waard, J W D, Heisterkamp, J, van Hillo, M, Kouwenhoven, E A, Liem, M S L, van der Peet, D L, Pierie, J P E N, Plukker, J T M, Roumen, R M H, Tetteroo, G W M, and van Workum, F

Published
2019

39. Transrectus sheath pre-peritoneal (TREPP) procedure versus totally extraperitoneal (TEP) procedure and Lichtenstein technique: a propensity-score-matched analysis in Dutch high-volume regional hospitals.

Author

Zwols, T. L. R., Slagter, N., Veeger, N. J. G. M., Möllers, M. J. W., Hess, D. A., Jutte, E., Brandsma, H. T., Veldman, P. H. J. M., Koning, G. G., Eker, H. H., and Pierie, J. P. E. N.

Subjects
POSTOPERATIVE pain, SURGICAL site, SURGICAL complications, INGUINAL hernia, HOSPITALS
Abstract

Purpose: Results of the most commonly used inguinal hernia repair techniques often originate from expert centers or from randomized controlled studies. In this study, we portray daily-practice results of a high-volume, regional surgical group in the Netherlands, comparing TREPP (open (posterior) transrectus sheath pre-peritoneal) with Lichtenstein (open anterior) and TEP (endoscopic (posterior) totally extraperitoneal). We hypothesize that the TREPP shows more favorable outcome compared to the current gold standard procedures: TEP and Lichtenstein. Methods: Between January 2016 and December 2018, 3285 consecutive patients underwent surgical treatment and were included for analysis. The outcome measures were postoperative pain, recurrence rate and other surgical complications. Propensity-score matching was used to address potential selection bias. Results: After propensity-score matching, there was no statistically significant difference in postoperative pain in the TREPP group compared to the Lichtenstein group (TREPP 7.3% versus Lichtenstein 6.3%; p = 0.67) nor in TREPP compared to TEP (TREPP 7.4% versus TEP 4.1%; p = 0.064). There was no statistically significant difference in recurrences in the TREPP group compared to Lichtenstein (3.8% vs 2.5%; p = 0.42), nor in the TREPP versus TEP comparison (3.9% vs 2.8%; p = 0.55) Conclusion: This study compares TREPP with Lichtenstein and TEP in the presence of postoperative pain, recurrences and other adverse outcomes. After propensity-score matching, no statistically significant difference in postoperative pain or recurrences remained between either TREPP compared to Lichtenstein, or TREPP compared to TEP. Based on these results, TREPP, Lichtenstein and TEP showed comparable results in postoperative pain, recurrences and other surgical site complications. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

42. Evaluation of PET and laparoscopy in STagIng advanced gastric cancer : A multicenter prospective study (PLASTIC-study)

Author

Brenkman, H. J.F., Gertsen, E. C., Vegt, E., van Hillegersberg, R., van Berge Henegouwen, M. I., Gisbertz, S. S., Luyer, M. D.P., Nieuwenhuijzen, G. A.P., van Lanschot, J. J.B., Lagarde, S. M., de Steur, W. O., Hartgrink, H. H., Stoot, J. H.M.B., Hulsewe, K. W.E., Spillenaar Bilgen, E. J., van Det, M. J., Kouwenhoven, E. A., van der Peet, D. L., Daams, F., van Sandick, J. W., van Grieken, N. C.T., Heisterkamp, J., van Etten, B., Haveman, J. W., Pierie, J. P., Jonker, F., Thijssen, A. Y., Belt, E. J.T., van Duijvendijk, P., Wassenaar, E., van Laarhoven, H. W.M., Wessels, F. J., Haj Mohammad, N., van Stel, H. F., Frederix, G. W.J., Siersema, P. D., Ruurda, J. P., on behalf of the PLASTIC Study Group, Brenkman, H. J.F., Gertsen, E. C., Vegt, E., van Hillegersberg, R., van Berge Henegouwen, M. I., Gisbertz, S. S., Luyer, M. D.P., Nieuwenhuijzen, G. A.P., van Lanschot, J. J.B., Lagarde, S. M., de Steur, W. O., Hartgrink, H. H., Stoot, J. H.M.B., Hulsewe, K. W.E., Spillenaar Bilgen, E. J., van Det, M. J., Kouwenhoven, E. A., van der Peet, D. L., Daams, F., van Sandick, J. W., van Grieken, N. C.T., Heisterkamp, J., van Etten, B., Haveman, J. W., Pierie, J. P., Jonker, F., Thijssen, A. Y., Belt, E. J.T., van Duijvendijk, P., Wassenaar, E., van Laarhoven, H. W.M., Wessels, F. J., Haj Mohammad, N., van Stel, H. F., Frederix, G. W.J., Siersema, P. D., Ruurda, J. P., and on behalf of the PLASTIC Study Group

Published
2018

43. Evaluation of PET and laparoscopy in STagIng advanced gastric cancer: A multicenter prospective study (PLASTIC-study)

Author

Brenkman, H.J.F. (Hylke J.F.), Gertsen, E.C. (E. C.), Vegt, E. (Erik), Hillegersberg, R. (Richard) van, van Berge Henegouwen, M.I., Gisbertz, S.S. (Suzanne S.), Luyer, M. (Misha), Nieuwenhuijzen, G.A.P. (Gerard), Lanschot, J.J.B. (Jan) van, Lagarde, S.M. (Sjoerd), de Steur, W.O. (Wobbe O.), Hartgrink, H.H. (H.), Stoot, J.H.M.B. (Jan), Hulsewé, K.W.E. (Karel W.E.), Spillenaar Bilgen, E.J. (Ernst Jan), van Det, M.J. (Marc J.), Kouwenhoven, E.A. (Ewout), Peet, D.L. (Donald) van der, Daams, F. (Freek), Sandick, J.W. (J.) van, Grieken, N.C.T. (Nicole), Heisterkamp, J. (Joos), Etten, B. (Boudewijn) van, Haveman, J.W., Pierie, J.-P.E.N. (Jean-Pierre), Jonker, F. (F.), Thijssen, A.Y. (A. Y.), Belt, E.J.T. (Eric), Duijvendijk, P. (Peter) van, Wassenaar, E. (E.), Laarhoven, H.W.M. (Hanneke) van, Wessels, F.J. (F. J.), Haj Mohammad, N. (Nadia), Stel, H.F. (Henk) van, Frederix, G.W.J. (Geert), Siersema, P.D. (Peter), Ruurda, J.P. (Jelle), Brenkman, H.J.F. (Hylke J.F.), Gertsen, E.C. (E. C.), Vegt, E. (Erik), Hillegersberg, R. (Richard) van, van Berge Henegouwen, M.I., Gisbertz, S.S. (Suzanne S.), Luyer, M. (Misha), Nieuwenhuijzen, G.A.P. (Gerard), Lanschot, J.J.B. (Jan) van, Lagarde, S.M. (Sjoerd), de Steur, W.O. (Wobbe O.), Hartgrink, H.H. (H.), Stoot, J.H.M.B. (Jan), Hulsewé, K.W.E. (Karel W.E.), Spillenaar Bilgen, E.J. (Ernst Jan), van Det, M.J. (Marc J.), Kouwenhoven, E.A. (Ewout), Peet, D.L. (Donald) van der, Daams, F. (Freek), Sandick, J.W. (J.) van, Grieken, N.C.T. (Nicole), Heisterkamp, J. (Joos), Etten, B. (Boudewijn) van, Haveman, J.W., Pierie, J.-P.E.N. (Jean-Pierre), Jonker, F. (F.), Thijssen, A.Y. (A. Y.), Belt, E.J.T. (Eric), Duijvendijk, P. (Peter) van, Wassenaar, E. (E.), Laarhoven, H.W.M. (Hanneke) van, Wessels, F.J. (F. J.), Haj Mohammad, N. (Nadia), Stel, H.F. (Henk) van, Frederix, G.W.J. (Geert), Siersema, P.D. (Peter), and Ruurda, J.P. (Jelle)

Abstract

Background: Initial staging of gastric cancer consists of computed tomography (CT) and gastroscopy. In locally advanced (cT3-4) gastric cancer, fluorodeoxyglucose positron emission tomography with CT (FDG-PET/CT or PET) and staging laparoscopy (SL) may have a role in staging, but evidence is scarce. The aim of this study is to evaluate the impact and cost-effectiveness of PET and SL in addition to initial staging in patients with locally advanced gastric cancer. Methods: This prospective observational cohort study will include all patients with a surgically resectable, advanced gastric adenocarcinoma (cT3-4b, N0-3, M0), that are scheduled for treatment with curative intent after initial staging with gastroscopy and CT. The modalities to be investigated in this study is the addition of PET and SL. The primary outcome of this study is the proportion of patients in whom the PET or SL lead to a change in treatment strategy. Secondary outcome parameters are: diagnostic performance, morbidity and mortality, quality of life, and cost-effectiveness of these additional diagnostic modalities. The study recently started in August 2017 with a duration of 36 months. At least 239 patients need to be included in this study to demonstrate that the diagnostic modalities are break-even. Based on the annual number of gastrectomies in the participating centers, it is estimated that approximately 543 patients are included in this study. Discussion: In this study, it is hypothesized that performing PET and SL for locally advanced gastric adenocarcinomas results in a change of treatment strategy in 27% of patients and an annual cost-reduction in the Netherlands of €916.438 in this patient group by reducing futile treatment. The results of this study may be applicable to all countries with comparable treatment algorithms and health care systems.

Published
2018
Full Text
View/download PDF

44. Evaluation of PET and laparoscopy in STagIng advanced gastric cancer: A multicenter prospective study (PLASTIC-study)

Author

MS CGO, Cancer, Divisie Beeld & Oncologie, MS Radiologie, MS Medische Oncologie, Verplegingswetenschap, Other research (not in main researchprogram), JC onderzoeksprogramma Methodologie, HEE, Child Health, Brenkman, H. J.F., Gertsen, E. C., Vegt, E., van Hillegersberg, R., van Berge Henegouwen, M. I., Gisbertz, S. S., Luyer, M. D.P., Nieuwenhuijzen, G. A.P., van Lanschot, J. J.B., Lagarde, S. M., de Steur, W. O., Hartgrink, H. H., Stoot, J. H.M.B., Hulsewe, K. W.E., Spillenaar Bilgen, E. J., van Det, M. J., Kouwenhoven, E. A., van der Peet, D. L., Daams, F., van Sandick, J. W., van Grieken, N. C.T., Heisterkamp, J., van Etten, B., Haveman, J. W., Pierie, J. P., Jonker, F., Thijssen, A. Y., Belt, E. J.T., van Duijvendijk, P., Wassenaar, E., van Laarhoven, H. W.M., Wessels, F. J., Haj Mohammad, N., van Stel, H. F., Frederix, G. W.J., Siersema, P. D., Ruurda, J. P., on behalf of the PLASTIC Study Group, MS CGO, Cancer, Divisie Beeld & Oncologie, MS Radiologie, MS Medische Oncologie, Verplegingswetenschap, Other research (not in main researchprogram), JC onderzoeksprogramma Methodologie, HEE, Child Health, Brenkman, H. J.F., Gertsen, E. C., Vegt, E., van Hillegersberg, R., van Berge Henegouwen, M. I., Gisbertz, S. S., Luyer, M. D.P., Nieuwenhuijzen, G. A.P., van Lanschot, J. J.B., Lagarde, S. M., de Steur, W. O., Hartgrink, H. H., Stoot, J. H.M.B., Hulsewe, K. W.E., Spillenaar Bilgen, E. J., van Det, M. J., Kouwenhoven, E. A., van der Peet, D. L., Daams, F., van Sandick, J. W., van Grieken, N. C.T., Heisterkamp, J., van Etten, B., Haveman, J. W., Pierie, J. P., Jonker, F., Thijssen, A. Y., Belt, E. J.T., van Duijvendijk, P., Wassenaar, E., van Laarhoven, H. W.M., Wessels, F. J., Haj Mohammad, N., van Stel, H. F., Frederix, G. W.J., Siersema, P. D., Ruurda, J. P., and on behalf of the PLASTIC Study Group

Published
2018

45. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial

Author

Noordman, Bo, Wijnhoven, Bas, Lagarde, Sjoerd, Boonstra, JJ, Coene, P, Dekker, JWT, Doukas, Michail, van der Gaast, Ate, Heisterkamp, J, Kouwenhoven, EA, Nieuwenhuijzen, GAP, Pierie, J, Rosman, C, van Sandick, JW, van der Sangen, MJC, Sosef, MN, Spaander, Manon, Valkema, R., van der Zaag, ES, Steyerberg, Ewout, van Lanschot, Jan, Noordman, Bo, Wijnhoven, Bas, Lagarde, Sjoerd, Boonstra, JJ, Coene, P, Dekker, JWT, Doukas, Michail, van der Gaast, Ate, Heisterkamp, J, Kouwenhoven, EA, Nieuwenhuijzen, GAP, Pierie, J, Rosman, C, van Sandick, JW, van der Sangen, MJC, Sosef, MN, Spaander, Manon, Valkema, R., van der Zaag, ES, Steyerberg, Ewout, and van Lanschot, Jan

Published
2018

46. Invasive extramammary Paget's disease and the risk for secondary tumours in Europe

Author

Van Der Zwan, J. M., Siesling, S., Blokx, W. A. M., Pierie, J. P. E. N., Capocaccia, R., Hackl, M., Zielonk, N., Van Eycken, E., Verstreken, M., Geissler, Jan, Znor, A., Magi, M., Hakulinen, T., Hedelin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Colonna, M., Moliniã©, F., Lacour, B., Desandes, E., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Benhamou, E., Holleczek, B., Wartenberg, Markus, Tryggvadottir, L., Comber, H., Deady, S., Bellã¹, F., Giacomin, A., Pascucci, C., Ferretti, S., Serraino, D., Vercelli, M., Quaglia, A., Vitarelli, S., Federico, M., Cirilli, C., Fusco, M., Traina, A., Michiara, M., Bozzani, F., Pastore, G., Tumino, R., Mangone, L., Falcini, F., Foca, F., Senatore, G., Iannelli, A., Budroni, M., Rosso, S., Piffer, S., Franchini, S., Crocetti, E., Caldarella, A., La Rosa, F., Stracci, F., Contiero, P., Tagliabue, G., Zambon, P., Fiore, A., Berrino, F., Casali, P. G., Gatta, G., Licitra, L., Ruzza, M., Sowe, S., Trama, A., De Angelis, R., Mallone, S., Tavilla, A., Dei Tos, A. P., Fleming, J., England, K., Langmark, F., Bray, F., Rachtan, J., Mezyk, R., Zwierko, M., Bielska-Lasota, M., Slowinski, J., Miranda, A., Primic-Žakelj, M., Ondrusova, M., Mateos, A., Izarzugaza, I., Torella-Ramos, A., Zurriaga, O., Marcos-Gragera, R., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Ardanaz, Eva, Moreno, C., Peris-Bonet, R., Galceran, J., Virizuela-Echaburu, J. A., Gonzalez-Campora, R., Martinez-Garcia, C., Melchor, J. M., Klint, Ã. …., Talbã¤ck, M., Adolfsson, Jan, Lambe, M., Mã¶ller, T. R., Ringborg, Ulrik, Jundt, G., Usel, M., Bouchardy, C., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Dehler, S., Probst-Hensch, N. M., Lutz, J. M., Visser, O., Otter, R., Coebergh, J. W. W., Greenberg, D. C., Forman, D., Roche, M., Stiller, C., Verne, J., Meechan, D., Lawrence, G., Coleman, M. P., Gavin, A., Brewster, D. H., Black, R. J., Kunkler, I., Steward, J., and Faculty of Behavioural, Management and Social Sciences

Subjects
Male, Epidemiology, Paget Disease, Disease, Extramammary Paget's, Neoplasms, 80 and over, Medicine, Aged, 80 and over, Europe, Rare tumours, Second cancer risk, Adult, Aged, Female, Humans, Incidence, Middle Aged, Neoplasm Invasiveness, Neoplasms, Second Primary, Paget Disease, Extramammary, Prognosis, Risk, Survival Rate, Surgery, Oncology, IR-81781, METIS-284549, Relative survival, Incidence (epidemiology), General Medicine, Second primary cancer, Second Primary, Standardized rate, medicine.medical_specialty, Socio-culturale, Extramammary Paget's disease, Translational research [ONCOL 3], Survival rate, Invasive extramammary Paget's disease, business.industry, medicine.disease, Dermatology, Extramammary, risk for secondary tumours, business
Abstract

Item does not contain fulltext The aim of this study was to determine the incidence and survival of Extramammary Paget's disease (EMPD) and to describe the possible increased risk of tumours after EMPD. All invasive cases diagnosed between 1990 and 2002 were selected from the RARECARE database. Incidence was expressed in European standardized rates. Relative survival was calculated for the period 1995-1999, with a follow-up until 31st December 2003. Standardized incidence ratios of second primary tumours were calculated to reveal possible increased risk after EMPD. European age standardized Incidence of EMPD within Europe is 0.6 per 1000,000 person years. Five-year relative survival for invasive EMPD was 91.2% (95%CI; 83.5-95.4), 8.6 percent of the EMPD patients developed other malignancies. The highest increased risk of developing a second primary tumour was found in the first year of follow-up (SIR:2.0 95%CI; 1.3-2.9), living in the South European region (SIR:2.3 95%CI; 1.5-3.5) or being female (SIR:1.5 95%CI; 1.1-1.9). Female genital organs displayed greatest increased risk of developing a second primary tumour after EMPD (SIR:15,1 95%CI; 0.38-84.23). Due to the increased risk of a second primary tumour after EMPD a thorough search for other tumours during their follow-up is recommended. 01 maart 2012

Published
2012

47. O-018 Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomised phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC)

Author

Ruers, T., primary, Punt, C.J.A., additional, van Coevorden, F., additional, Pierie, J.-P., additional, Borel Rinkes, I., additional, Ledermann, J., additional, Poston, G., additional, Bechstein, W., additional, Lentz, M.-A., additional, Mauer, M., additional, Van Cutsem, E., additional, Lutz, M., additional, and Nordlinger, B., additional

Published
2015
Full Text
View/download PDF

49. Impact of Endoscopic Ultrasonography on F-FDG-PET/CT Upfront Towards Patient Specific Esophageal Cancer Treatment.

Author

Hulshoff, J., Mul, V., Boer, H., Noordzij, W., Korteweg, T., Dullemen, H., Nagengast, W., Oppedijk, V., Pierie, J., and Plukker, John

Abstract

Introduction: In patients with potentially resectable esophageal cancer (EC), the value of endoscopic ultrasonography (EUS) after fluorine-18 labeled fluorodeoxyglucose positron emission tomography with computed tomography (F-FDG-PET/CT) is questionable. Retrospectively, we assessed the impact of EUS after PET/CT on the given treatment in EC patients. Methods: During the period 2009-2015, 318 EC patients were staged as T1-4aN0-3M0 with hybrid F-FDG-PET/CT or F-FDG-PET with CT and EUS if applicable in a nonspecific order. We determined the impact of EUS on the given treatment in 279 patients who also were staged with EUS. EUS had clinical consequences if it changed curability, extent of radiation fields or lymph node resection (AJCC stations 2-5), and when the performed fine-needle aspiration (FNA) provided conclusive information of suspicious lymph node. Results: EUS had an impact in 80 (28.7%) patients; it changed the radiation field in 63 (22.6%), curability in 5 (1.8%), lymphadenectomy in 48 (17.2%), and FNA was additional in 21 (7.5%). In patients treated with nCRT ( n = 194), EUS influenced treatment in 53 (27.3%) patients; in 38 (19.6%) the radiation field changed, in 3 (1.5%) the curability, in 35 (18.0%) the lymphadenectomy, and in 17 (8.8%) FNA was additional. EUS influenced both the extent of radiation field and nodal resection in 31 (16.0%) nCRT patients. Conclusions: EUS had an impact on the given treatment in approximately 29%. In most patients, the magnitude of EUS found expression in the extent of radiotherapy target volume delineation to upper/high mediastinal lymph nodes. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results